FusionPharm to open Seattle Sales Center
24 Mars 2014 - 1:00PM
FusionPharm, Inc, (OTC) FSPM (www.fusionpharminc.com), the Denver
based manufacturer of the PharmPods™ cultivation system
(www.pharmpods.com) has leased space in Seattle's SoDo warehouse
district in anticipation of opening its first Washington State
design and sales center later this spring.
"The opening of our Seattle location marks an important
milestone for FusionPharm as we begin to open sales centers in each
new, major marketplace" commented FusionPharm CEO Scott
Dittman.
"Our Denver design and sales center is our most
important tool for introducing clients to PharmPods," explained
Sales Manager John Scott. "We are very excited to be opening a
similar facility in Washington state, where we can showcase two
fully fuctioning PharmPods to potential customers in the Northwest.
We encourage everyone to join us at our grand opening celebration
in mid-May to see why PharmPods™ are already the choice of
professional cultivators in 4 states and in Canada, " concluded Mr.
Scott.
The lease term begins April 1st and FusionPharm anticipates
completion of construction activities in approximately 6 weeks.
About FusionPharm Inc. (FSPM)
FusionPharm, Inc. (FSPM) (www.fusionpharminc.com) was organized
to capitalize on opportunities present in the rapidly growing
vertical farming and cannabis industries. FusionPharm's primary
focus is the development and deployment of the patent pending
PharmPods™ advanced hydroponic commercial cultivation systems.
PharmPods are constructed from standard ISO steel shipping
containers that are repurposed for use in indoor controlled
environment agriculture. Modular, stackable, cost competitive and
financeable, PharmPods have become the industry leader for
professional, commercial scale indoor plant cultivation.
NOTES ABOUT FORWARD-LOOKING STATEMENTS: Except
for any historical information contained herein, the matters
discussed in this press release contain forward-looking statements
that involve risks and uncertainties, including those described in
the Company's Securities and Exchange Commission reports and
filings. Certain statements contained in this release that are not
historical facts constitute forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995,
and are intended to be covered by the safe harbors created by that
Act. Reliance should not be placed on forward-looking statements
because they involve unknown risks, uncertainties and other
factors, which may cause actual results, performance or
achievements to differ materially from those expressed or implied.
Forward-looking statements may be identified by words such as
estimates, anticipates, projects, plans, expects, intends,
believes, should and similar expressions and by the context in
which they are used. Such statements are based upon current
expectations of the Company and speak only as of the date made. The
Company undertakes no obligation to update any forward-looking
statements to reflect events or circumstances after the date on
which they are made.
CONTACT: investors@fusionpharminc.com
sales@pharmpods.com
Fusion Pharm (CE) (USOTC:FSPM)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Fusion Pharm (CE) (USOTC:FSPM)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024